Chi Sheng Pharma & Biotech Co., Ltd. (4111) AI Stock Analysis

Chi Sheng Pharma & Biotech Co., Ltd.

(TPEx:4111)

Select Model

Rating:73Outperform

Price Target:TWD 31.00▲(8.77% Upside)

Action:initiatedcoverage

Date:11/10/26

Strong financial performance and attractive valuation are the primary positive drivers, partially offset by weak technical momentum.

Positive Factors

Accelerating Revenue and MarginsThe recent combination of faster revenue growth and expanding profitability indicates stronger operating traction and improved earnings conversion. If maintained, higher margins can support reinvestment, strengthen resilience, and allow the company to compound earnings over the next several quarters.

Negative Factors

Earnings and Revenue VolatilityThe uneven history makes it harder to determine how durable the latest growth and margin gains are. Previous revenue contraction and margin compression suggest that earnings power can fluctuate materially, creating uncertainty around the consistency of results over coming quarters.

Chi Sheng Pharma & Biotech Co., Ltd. (4111) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.71B
Dividend Yield: 4.56%
Average Volume (3M): 64.01K
Price to Earnings (P/E): 9.2
Beta (1Y): 0.15
Revenue Growth: 5.33%
EPS Growth: 13.75%
Country: TW
Employees: 80
Sector: General
Sector Strength: 55
Industry: Medical - Instruments & Supplies

Chi Sheng Pharma & Biotech Co., Ltd. Business Overview & Revenue Model

Company Description

Chi Sheng Pharma & Biotech Co., Ltd. is a Taiwan-based company actively engaged in the development, production, distribution, and international trade of a diverse range of products. Operating across both domestic and global markets, the company speci...

Chi Sheng Pharma & Biotech Co., Ltd. Financial Statement Overview

Summary

Revenue growth and margin expansion combined with a very strong low-debt balance sheet and solid cash flow generation support healthy financial performance.

Income Statement

76Positive

Balance Sheet

91Very Positive

Cash Flow

83Very Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.42B	1.38B	1.17B	1.06B	1.14B	1.02B
Gross Profit	533.27M	507.61M	397.18M	343.10M	422.51M	356.58M
EBITDA	287.29M	271.75M	204.56M	150.75M	236.69M	211.94M
Net Income	189.06M	164.28M	110.63M	68.67M	154.01M	80.75M
Balance Sheet
Total Assets	2.04B	1.94B	1.75B	1.77B	1.80B	1.66B
Cash, Cash Equivalents and Short-Term Investments	472.29M	443.91M	336.19M	381.05M	456.25M	252.27M
Total Debt	44.98M	48.77M	185.94M	122.90M	290.38M	292.20M
Total Liabilities	634.64M	557.04M	475.08M	547.04M	578.38M	559.04M
Stockholders Equity	1.40B	1.38B	1.27B	1.22B	1.22B	1.10B
Cash Flow
Free Cash Flow	220.81M	315.19M	127.98M	-26.98M	109.00M	-126.18M
Operating Cash Flow	307.65M	409.05M	213.20M	74.52M	214.86M	139.33M
Investing Cash Flow	-88.41M	-97.17M	-86.31M	-76.61M	63.24M	-289.02M
Financing Cash Flow	-69.79M	-204.17M	-171.75M	-73.11M	-74.88M	66.68M

Chi Sheng Pharma & Biotech Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4111 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4111	73Outperform	TWD 1.71B	9.16	―	4.56%	5.33%	13.75%
TW:4153	69Neutral	TWD 1.74B	15.93	―	6.48%	9.73%	36.89%
TW:1294	67Neutral	TWD 1.62B	11.43	―	6.70%	20.43%	4.47%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6558	47Neutral	TWD 1.81B	-10.57	―	1.55%	-10.07%	-349.71%

* General Sector Average

Performance Comparison

TW:4111 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4111	Chi Sheng Pharma & Biotech Co., Ltd.	28.50	-0.20	-0.71%
TW:1294	Hantech Bio-Technology Co., Ltd.	44.80	-14.06	-23.88%
TW:4153	Diva Laboratories, Ltd.	30.85	-1.80	-5.51%
TW:6558	SYNergy ScienTech Corp.	19.45	-18.05	-48.13%
TW:6659	Timing Pharmaceutical Co. Ltd.	20.20	-19.76	-49.44%
TW:6917	Andros Pharmaceuticals Co., Ltd.	31.00	6.90	28.63%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Chi Sheng Pharma & Biotech Co., Ltd. AI Stock Analysis